Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$123.46 USD
-3.67 (-2.89%)
Updated May 24, 2024 04:00 PM ET
After-Market: $123.49 +0.03 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
Sarepta Therapeutics, Inc. [SRPT]
Reports for Purchase
Showing records 201 - 220 ( 661 total )
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Thoughts on Year-One Outcomes With SRP-9001
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
rh74 + MHCK7 Proving to Be the Vector + Promoter of Choice for Muscular Dystrophies
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
PF-0693992 Take Two; Kinetics of Response Not as Impressive as SRP-9001
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Take on PF-06939926; Pfizer Should Buy Alexion and Make Soliris Available at No Cost
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Previewing 1Q20; Updates on Manufacturing and Timing of Commercial Study Supply Key to Sentiment
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHATTOPADHYAY D
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sarepta Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for SRPT.
Provider: Stock Traders Daily
Analyst: Research Department